RH Earnings Recaps
Q1 2026
May 6, 2026
The stock surged 12.9% following a quarter that demonstrated clear initial traction with the newly approved acquired hypothalamic obesity (HO) indication, a significantly larger market opportunity than Bardet-Biedl syndrome (BBS). Early launch metrics and payer receptivity for HO drove optimism about Rhythm’s commercial expansion and long-term growth potential.
Key takeaways
- Q1 revenues reached $60 million, reflecting steady growth in the base BBS business despite it being an ultra-rare disease.
- The acquired HO launch is off to a solid start with over 150 patient start forms submitted since the March approval, indicating strong physician and payer engagement.
- Commercial infrastructure expanded substantially, with sales reps increasing from 16 (BBS) to 42 (HO), signaling Rhythm’s commitment to capturing the larger HO patient population (~10,000 estimated in U.S. and Europe).
- Positive early data from Japan and anticipated regulatory approval before year-end reinforce the global growth thesis for HO.
- Upcoming clinical data presentations and planned Phase III trial initiation aim to sustain momentum and expand the therapeutic portfolio in HO and Prader-Willi syndrome.
Q3 2025
Nov 6, 2025
Rhythm Pharmaceuticals reported strong Q3 2025 performance, highlighted by significant growth in IMCIVREE revenue and strategic advancements in their product pipeline, positioning the company for upcoming launches.
Key takeaways
- IMCIVREE sales reached $51.3 million, marking a 10% increase in reimbursed therapy patients.
- Successful completion of a $189 million equity offering in July to strengthen the balance sheet ahead of key regulatory developments.
- Regulatory filings for hypothalamic obesity (HO) accepted by both the FDA and EMEA, with a PDUFA date set for December 20, 2025.
- Upcoming preliminary results from the Phase II trial in Prader-Willi syndrome expected by year-end, aimed at demonstrating efficacy in BMI reduction.
- Expansion of the commercial team in preparation for the HO launch, targeting an estimated 10,000 patients in the U.S. market.